Abstract: A device (14) for fusing sensor data with map data, includes: an input interface (24) for receiving sensor data of a surroundings sensor (18) with information regarding objects in the surroundings of a vehicle (12) and for receiving map data with information regarding the vehicle surroundings; an evaluation unit (26) for recognizing visible traffic signs (20) in the vehicle surroundings on the basis of the sensor data and for reading out known traffic signs in the vehicle surroundings from the map data; and an assignment unit (28) for assigning the visible traffic signs to the known traffic signs and for determining a certainty parameter which indicates a probability of a correct assignment.

Abstract: An optical device and the prism module thereof are provided. The prism module includes a first prism, a second prism, and a third prism. The second prism is disposed beside the first prism. The third prism is adhered to the second prism. First light enters the first prism, is reflected plural times in the first prism, enters the second prism, and is emitted from the second prism. Second light enters the second prism, is reflected plural times in the second prism, and is emitted from the second prism. Third light sequentially passes through the third prism and the second prism, enters the first prism, is reflected plural times in the first prism, and is emitted from the first prism.

Abstract: Disclosed is a pyridazinone compound represented by Formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, stereoisomer, or isotopic variant thereof. The compound can be used for preparation of medicinal products for treatment and/or prophylaxis of a disease or condition associated with thyroid hormone abnormalities. The compound has higher selectivity to TH?, better pharmacokinetic parameters, desired stability, and higher agonistic activity toward TH?.

Abstract: A method for the reaction of an isatin and cyclopropenone compound at low catalytic amount. In the presence of an amine compound and phosphite, the isatin and cyclopropenone are reacted in an organic solvent using a silicon amino rare earth compound as a catalyst to synthesize pyrano[2,3-b]indol-2-one compounds. In the reaction above, the amount of catalyst is few, and noble metal is not needed for catalysis. The present method can achieve preparation of the pyrano[2,3]indol-2-one compound efficiently and simply.

Abstract: The present disclosure provides a base plate integrating passive devices and a method for manufacturing the same, which relate to the technical field of radio frequency devices. The base plate integrating passive devices of the present disclosure includes a substrate base plate and the passive devices disposed on the substrate base plate, the passive devices including at least an inductor, the inductor including a plurality of open ring portions arranged and connected in sequence in a direction away from the base plate, wherein an interlayer dielectric layer is disposed between the open ring portions disposed adjacently, and the open ring portions disposed adjacently are electrically connected through a first via hole penetrating the interlayer dielectric layer; orthographic projections of any two of the open ring portions on the substrate base plate at least partially overlap.

Abstract: Methods and systems for a unified application notification framework are described herein. A server may receive a notification from a service provider. The service provider may be associated with an application executable on a virtual machine. The virtual machine may be part of a virtual environment that includes a user interface. The server may determine an identifier for the received notification. The identifier may indicate the application on the virtual machine associated with the service provider. The server may provide the received notification to the user interface for display to a user. The received notification may be displayed without execution of the application on the virtual machine.

Abstract: Methods and systems for a unified application notification framework are described herein. A server may receive a notification from a service provider. The service provider may be associated with an application executable on a virtual machine. The virtual machine may be part of a virtual environment that includes a user interface. The server may determine an identifier for the received notification. The identifier may indicate the application on the virtual machine associated with the service provider. The server may provide the received notification to the user interface for display to a user. The received notification may be displayed without execution of the application on the virtual machine.

Abstract: Methods and systems for a unified application notification framework are described herein. A server may receive a notification from a service provider. The service provider may be associated with an application executable on a virtual machine. The virtual machine may be part of a virtual environment that includes a user interface. The server may determine an identifier for the received notification. The identifier may indicate the application on the virtual machine associated with the service provider. The server may provide the received notification to the user interface for display to a user. The received notification may be displayed without execution of the application on the virtual machine.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.